Cidara Therapeutics, Inc. (CDTX) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 8 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for CDTX is $57.00, representing a -74.3% downside from the current price of $221.38. Price targets range from a low of $46.00 to a high of $68.00.
